MARKET

ASLN

ASLN

Aslan Pharms
NASDAQ
0.7995
+0.1495
+23.00%
After Hours: 0.7898 -0.0097 -1.21% 18:23 03/18 EDT
OPEN
0.6800
PREV CLOSE
0.6500
HIGH
0.8000
LOW
0.6400
VOLUME
1.77M
TURNOVER
0
52 WEEK HIGH
4.690
52 WEEK LOW
0.3920
MARKET CAP
13.33M
P/E (TTM)
-0.2660
1D
5D
1M
3M
1Y
5Y
Aslan Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 18h ago
Aslan Pharmaceuticals Price Target Cut to $9.00/Share From $17.00 by HC Wainwright & Co.
Dow Jones · 18h ago
Weekly Report: what happened at ASLN last week (0311-0315)?
Weekly Report · 18h ago
HC Wainwright & Co. Maintains Buy on ASLAN Pharma, Lowers Price Target to $9
Benzinga · 18h ago
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)
TipRanks · 19h ago
Week In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIO
Germany's Boehringer Ingelheim acquired an option to license drug candidates that treat all symptoms of schizophrenia. WuXi AppTec forced to resign from BIO due to pressure from the US Congress. ChinaBio filed for a Hong Kong IPO to support commercialization of its diabetes and obesity drug.
Seeking Alpha · 1d ago
Piper Sandler Reiterates Overweight on ASLAN Pharma, Lowers Price Target to $10
Benzinga · 5d ago
Aslan Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
More
About ASLN
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Webull offers Aslan Pharmaceuticals Ltd (ADR) stock information, including NASDAQ: ASLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ASLN stock methods without spending real money on the virtual paper trading platform.